44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
41 citations
,
July 2001 in “PubMed” Estrogens can reduce DHT production in hair follicles, but are less effective than finasteride and progesterone.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
January 2019 in “Dermatologica Sinica” Dutasteride improved both hair loss and acne in two young men.
15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride doesn't affect erections much, but may decrease libido in men.
16 citations
,
October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Dutasteride may protect the brain in early Parkinson's disease.
63 citations
,
December 2013 in “PLoS ONE” Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
6 citations
,
August 2005 in “The Journal of Clinical Endocrinology & Metabolism” Finasteride causes temporary cell death in BPH tissues.
22 citations
,
May 1986 in “Clinics in endocrinology and metabolism” Certain finger length ratios and body hair patterns may predict side effects from birth control pills in women.
11 citations
,
April 2020 in “Andrology” Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
35 citations
,
November 1989 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Epitestosterone may act as a weak antiandrogen and can inhibit an enzyme involved in testosterone metabolism.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
5 citations
,
September 2011 in “Andrologia” Finasteride use may be linked to rare testicular tumor, but more research needed.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
1 citations
,
January 2010 in “Endocrine abstracts” 1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
23 citations
,
January 2021 in “Biomedicine & Pharmacotherapy” DHT stops hair regrowth in mice, similar to human hair loss.
56 citations
,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
October 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” DA-9401 can protect against finasteride-induced reproductive damage in rats.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
3 citations
,
October 1995 in “International Journal of Dermatology” Finasteride helps treat skin issues like acne and baldness by blocking testosterone conversion.
39 citations
,
August 2004 in “International journal of gynaecology and obstetrics” Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.